<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">34724038</PMID><DateRevised><Year>2021</Year><Month>11</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1943-7722</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2021</Year><Month>Nov</Month><Day>01</Day></PubDate></JournalIssue><Title>American journal of clinical pathology</Title><ISOAbbreviation>Am J Clin Pathol</ISOAbbreviation></Journal><ArticleTitle>Cycle Threshold Probability Score for Immediate and Sensitive Detection of B.1.351 SARS-CoV-2 Lineage.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">aqab186</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/ajcp/aqab186</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern associated with immune escape is important to safeguard vaccination efficacy. We describe the potential of delayed N gene amplification in the Allplex SARS-CoV-2 Assay (Seegene) for screening of the B.1.351 (20H/501.V2, variant of concern 2 [VOC.V2], South African SARS-CoV-2 variant) lineage.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In a study cohort of 397 consecutive polymerase chain reaction-positive samples genotyped by whole-genome sequencing, amplification curves of E/N/S-RdRP targets indicated delayed  N vs E gene amplification characteristic of B.1.351. Logistic regression was used to calculate a VOC.V2 probability score that was evaluated as a separate screening test in an independent validation cohort vs sequencing.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">B.1.351 showed a proportionally delayed amplification of the  N vs E gene. In logistic regression, only N and E gene cycle thresholds independently contributed to B.1.351 prediction, allowing calculation of a VOC.V2 probability score with an area under the curve of 0.94. At an optimal dichotomous cutoff point of 0.12, the VOC.V2 probability score achieved 98.7% sensitivity at 79.9% specificity, resulting in a negative predictive value (NPV) of 99.6% and a positive predictive value of 54.6%. The probability of B.1.351 increased with an increasing VOC.V2 probability score, achieving a likelihood ratio of 12.01 above 0.5. A near-maximal NPV was confirmed in 153 consecutive validation samples.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Delayed N vs E gene amplification in the Allplex SARS-CoV-2 Assay can be used for fast and highly sensitive screening of B.1.351.</AbstractText><CopyrightInformation>© American Society for Clinical Pathology, 2021. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>De Smet</LastName><ForeName>Dieter</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, AZ Delta General Hospital, Roeselare, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vanhee</LastName><ForeName>Merijn</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, AZ Delta General Hospital, Roeselare, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maes</LastName><ForeName>Brigitte</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Clinical Biology, Jessa Hospital, Hasselt, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swaerts</LastName><ForeName>Koen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, AZ Delta General Hospital, Roeselare, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Jaeger</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, AZ Delta General Hospital, Roeselare, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maelegheer</LastName><ForeName>Karel</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Clinical Biology, AZ Sint-Lucas Hospital, Bruges, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Hoecke</LastName><ForeName>Frederik</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, AZ Delta General Hospital, Roeselare, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martens</LastName><ForeName>Geert Antoine</ForeName><Initials>GA</Initials><Identifier Source="ORCID">0000-0003-1208-6289</Identifier><AffiliationInfo><Affiliation>Department of Laboratory Medicine, AZ Delta General Hospital, Roeselare, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomolecular Medicine, Ghent University, Gent, Belgium.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Fagron (Nazareth, Belgium)</Agency><Country/></Grant><Grant><Agency>AZ Delta General Hospital</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>11</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Am J Clin Pathol</MedlineTA><NlmUniqueID>0370470</NlmUniqueID><ISSNLinking>0002-9173</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cycle threshold value</Keyword><Keyword MajorTopicYN="N">Data analysis</Keyword><Keyword MajorTopicYN="N">Modeling</Keyword><Keyword MajorTopicYN="N">PCR</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Secondary data analysis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>08</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>09</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>1</Day><Hour>16</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34724038</ArticleId><ArticleId IdType="pii">6415253</ArticleId><ArticleId IdType="doi">10.1093/ajcp/aqab186</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>